Island Pharmaceuticals Takes Stride in Antiviral Innovation with Initiation of ISLA-101 Study for Dengue Prevention and Treatment

Written By Kathleen Otto

Island Pharmaceuticals Ltd, a frontrunner in antiviral drug development, has commenced the first cohort dosing in its Single Ascending Dose study for ISLA-101. This groundbreaking initiative targets the prevention and treatment of dengue and other mosquito-borne diseases, showcasing the company's commitment to advancing innovative solutions in the field.

Kathleen Otto
Previous

OncoNano Medicine Achieves Milestone with First Patient Dosed in Phase 1 Trial for ONM-501 in Advanced Solid Tumors and Lymphomas
Next

Reviving the Dodo: Mauritian Wildlife Foundation and Colossal Biosciences Join Forces for Rewilding Efforts in Native Habitat